Navigation Links
Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations
Date:8/27/2009

patients discontinued the trial in the roflumilast group than those taking placebo (14 percent vs 11 percent). Diarrhoea, nausea and headache were the commonest reasons for discontinuation. A reduction in weight, around 2kg, was seen consistently across all the studies published in The Lancet. When patients stopped taking roflumilast the majority regained weight. In addition, in the 12- month studies, only four patients out of 1,547 dropped out because of weight loss.

Six-month trials

In the six-month trial patients used roflumilast or a placebo in conjunction with commonly used long acting bronchodilators (inhalers).

In one trial, patients used salmeterol with roflumilast or placebo. In the second trial, patients used tiotropium, a long-acting bronchodilator which also reduces the production of mucus, with roflumilast or placebo. Patients used "rescue medication" short-acting bronchodilators, as needed.

There were 933 patients in the salmeterol trial and 743 patients in the tiotropium trial. Overall patients had moderate to severe COPD; were over 40, current or former smokers with a history of smoking at least a pack a day for 10 years. In contrast to the 12-month trials, patients in the six-month trials did not require a history of exacerbations. Patients recruited to the tiotropium study were more symptomatic than those in the salmeterol study as they were required to have daily chronic cough and sputum production and a documented use of rescue medication.

Patients were seen and measured once a month for the first three months and every six weeks for the last three months of the trial.

Compared with placebo, patients taking roflumilast in addition to salmeterol, had an average increased pre-bronchodilator FEV(1) (forced expiratory volume in one second) of 49mL (p<0.001).

Compared with placebo, patients taking roflumilast in
'/>"/>

SOURCE Nycomed
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
2. Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
3. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
4. PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies
5. Infant Formula Company Teams With the University of Virginia Pediatrics Department to Conduct Clinical Studies
6. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
7. School of Dentistry Studies Link Between Oral Health and Memory
8. Cancer Treatment Centers of America(R) Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells
9. New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring
10. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
11. Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ... biology, human genetics, genomic technology, and drug discovery ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014 /PRNewswire/ ... "Lifetime in Dermatology Achievement Award" from the Journal ... Orlando Dermatology Aesthetic & Clinical Conference (ODAC). The event ... in Florida . ... comprehensive report on the practice of dermatology for clinical ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of ... able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Device Industry, it steadfastly remains one of ... involving IP infringement. This litigious nature can ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... Bedford Laboratories™, a division of Ben Venue Laboratories, ... Topotecan Hydrochloride for Injection, 4 mg (base)/vial to ... the reference listed drug Hycamtin ® (topotecan ... Injection is indicated for the treatment of metastic ...
... Nektar Therapeutics (Nasdaq: NKTR ) will announce ... 2011 on Wednesday, April 27, 2011, after the close of ... will host a conference call to review the results beginning ... The press release and a live audio-only ...
Cached Medicine Technology:Bedford Laboratories™ to Begin Shipping Topotecan Hydrochloride for Injection, 4mg SD Vial 2Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets 2
(Date:4/15/2014)... States have nearly doubled since 1988, suggests new research ... with obesity apparently to blame for the surge. The ... has not hit all groups equally, with alarming increases ... According to new research reported in the April 15, ... , diabetes increased from 6 percent to 10 percent ...
(Date:4/15/2014)... have solved a decades-old medical mystery and in the ... invasive fungal infections, which kill about 1.5 million people a ... action of amphotericin, an antifungal drug that has been in ... is nearly as toxic to human cells as it is ... of the new findings appears in Nature Chemical Biology ...
(Date:4/15/2014)... School of Medicine have identified a mechanism that explains ... disease and why the virus is able to persist ... hard-to-kill pathogen, which infects an estimated 200 million people ... mitochondria dismantling the cell,s innate ability to fight ... , The study, published in today,s issue of the ...
(Date:4/14/2014)... children orphaned by HIV/AIDS in South Africa may provide ... emotional behavior issues in other areas of the world, ... research that could lead to successful interventions. , ... the United Nations mentions that due to the HIV/AIDS ... Sub-Saharan African, children are at an increased risk for ...
(Date:4/14/2014)... Va., USA The International and American Associations ... titled "Rare Bone Diseases and Their Dental, Oral, ... Sunday O. Akintoye, Andrea B. Burke, Alison M. ... Gafni, Janice S. Lee, Mary Scott Ramnitz, Martha ... in the OnlineFirst portion of the IADR/AADR ...
Breaking Medicine News(10 mins):Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Breaking bad mitochondria 2Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2
... Practice Arm of the School,s Department of Forensic ... Jan. 30 The Chicago School of ... its psychology services to the legal sector and ... thanks to its new Forensic Center, which was ...
... Kroger Co. (NYSE: KR ),said today it is ... stores,because the product was associated with peanut butter supplied by ... Stores under the following names in ... Kroger, Ralphs, Fred Meyer, Food 4 Less, Fry,s,King Soopers, ...
... grid of small arteries at the surface of the brain ... supply to tissue starved of nutrients and oxygen following a ... is optimistic news," said David Kleinfeld, a physics professor at ... flow in animal models of stroke. , Damage from stroke ...
... ) AMDL, Inc. (NYSE Alternext US: ADL), a vertically ... the US, announced today the second and final closing ... notes and warrants. The exclusive placement agent for ... on December 8, 2008, AMDL sold $1,077,500 of 12% ...
... school shootings, other tragedies , , FRIDAY, Jan. 30 (HealthDay ... people into hotheads. , A University of Kentucky study ... likely to view other people,s actions as hostile and ... , The researchers said their findings may help explain ...
... up bad lipoproteins, researchers say , , FRIDAY, Jan. ... (HDL) -- the "good" cholesterol -- may hold ... the deadly cardiovascular disease it can cause. , ... is close in size to natural HDL with ...
Cached Medicine News:Health News:New Chicago School of Professional Psychology Forensic Center Opens Doors to the Community 2Health News:New Chicago School of Professional Psychology Forensic Center Opens Doors to the Community 3Health News:Kroger Recalls Nut Topping Due to Possible Health Risk 2Health News:Mesh-like network of arteries adjusts to restore blood flow to stroke-injured brain 2Health News:AMDL, Inc. Announces Final Closing of Private Placement of Senior Notes 2Health News:AMDL, Inc. Announces Final Closing of Private Placement of Senior Notes 3Health News:Those Who Feel Rejected Direct Hostility Toward Others 2Health News:Synthetic HDL Could Fight Heart Disease 2
... Detection Reagents provide molecular labs a more ... By using our MGB technology, combined with ... now able to provide molecular labs more ... of specific organisms or genetic mutations associated ...
... MGB Alert Detection Reagents provide molecular labs ... based assays. By using our MGB technology, ... Nanogen is now able to provide molecular ... acid sequences of specific organisms or genetic ...
... and most advanced fecal occult blood test ... immunochemical FOBT (iFOBT) with high specificity and ... detect bleeding associated with more cancers and ... its superior specificity for lower GI bleeding, ...
... Capture vital signs faster, easier, ... Signs LXi, the latest innovation in ... With Spot LXi, you get more ... the flexibility to customize it to ...
Medicine Products: